SOCOMER

ABOUT SOCOMER

Society for Continuing Medical Education and Research is a Registered Society under 12th Travancore-Cochin Literary, Scientific and Charitable Societies Act of 1955 on 6th September 2000 with the following major aims and objectives:-
 
To organize Continuing Medical Education programmes in various medical specialties at State, National and International level.
To assist medical institutes to conduct special studies and to develop research projects
To plan and execute research projects in various medical institutes
To avail of the expertise of faculty members from various nationally and internationally reputed Universities and Institutions etc.
To provide thesis guidance to Under Graduate and Post Graduate Medical students, M.Sc. Nursing students and Paramedical students.
 
The society currently carries out State, National & International level Continuing Medical Education Programs like Seminars, Conferences, Symposia & Workshops, conducting short term courses for doctors, nurses and other paramedical professionals like PALS, NALS etc. The Society in association with foreign universities like Irkutsk State Medical University and Peoples friends University, Russia, carries out Students exchanges programs, PhD programs, Internship programs and conducts of joint research projects. The Society is also responsible for carrying out the conduct of Institutional Human Ethics Committee of KIMS and thereby making sure that the Clinical Research Projects are run according to the Indian Council of Medical Research Guidelines. 

SOCOMER Programmes: A Retrospect for the year April 2011 – March 2012

CME Programmes, Conferences & Seminars
 

• KIMS Pinnacle Cancer Update 2011-“Carcinoma Cervix” on 6th April 2011

• Cardiology CME at Kollam on 4th June 2011

• CME on “Antibiotic Resistance in India” on 18th June 2011

• CME on “Antibiotics in ENT” on 01st August 2011

• Zonal Round NNF ( PG/Nursing) Quiz 2011 on 7th August 2011

• CME on “Approach to Neurogenic Bladder” on 12th August 2011

• CME on “Emergency Trauma Care” on 18th September 2011

• Updates on “Cervical Cancer Vaccination” on 29th October 2011

• CME on “Newer Concepts in Breast Cancer” on 29th  October 2011

• CME on “Parenteral Nutrition in New Born” on 30th October 2011

• CME on “Management of Fungal Infections” on 24th November 2011

• KIMS Presentation at TVM Cardiology Club Meeting on 26th November 2011

• CME on “Prevention of Parent to Child Transmission of HIV” 1st December 2011

• CME on “Pregnancy and Rheumatic Diseases and Antiphospholipid Syndrome in Pregnancy” on 3rd February 2012

• CME on “New Advances in Insulin Therapy” on 4th February 2012

• CME on “Nutrition of Hospitalized Patients” on 17th February 2012

• NNF Conference: Neocon 12 on 18th & 19th February 2012

• CME on “Poliomyelitis” on 23rd February 2012

• CME on “Surgical Site Infections” on 25th February 2012

• Neonatal Nursing CME on “Effective Communication and Counseling”  on 3rd March 2012

• CME on “ECHOES 2012” on 18th March 2012

• CME on “Atopic Dermatitis”  on 22nd March 2012
  
  Workshops

• Workshop on “Neonatal Catheterization and Maintenance” on 17th April 2011

• International Conference & Workshop on “Perinatal Medicine-The need of the Nation” on 30th March and 1st May   2011

• Workshop on Biostatistics on 13th & 14th June 2011

• Workshop on Thesis Protocol Preparation on 3rd July 2011

• International Workshop on “Latest Innovations in Total Knee Replacement” 7th, 8th & 9th October 2011

Clinical Club Meetings

• Clinical  Club Meeting held on  27th April 2011

• Orthopaedics Clinical Club Meeting on 4th May 2011

• Clinical Club Meeting 0n 25th May 2011

• Clinical Club Meeting-Internal Medicine on  29th June 2011

• Clinical Club Meeting-Internal Medicine on 25th July 2011

• Clinical Club Meeting on 29th July 2011

• Clinical Club Meeting on 24th August 2011

• Clinical Club Meeting-Internal Medicine on 29th August 2011

• Clinical Club Meeting on 28th October 2011

• Clinical Club Meeting on 23rd November 2011

• Clinical Club Meeting on 28th December 2011

• Clinical Club Meeting on 25th January 2012

• Clinical Club Meeting on 22nd February 2012

• Clinical Club Meeting on 28th March 2012
  
  Clinicopathological Meetings

• Clinicopathological Meeting on 2nd November 2011

• Clinicopathological Meeting on 1st December 2011

• Clinicopathological Meeting on 4th January 2012

• Clinicopathological Meeting on 1st February 2012

• Clinicopathological Meeting on 7th March 2012

Web Casts

• Web Cast on “Paediatric Resperatory Diseases on 31st July 2011

• Direct Web Cast from KIMS on “Intact Outcome in Intensive Care” on 6th August 2011

• Webcast on “Maternal and Child Health” on 16th March 2012

• Special Day Observations

• World Paediatric Asthma Day Celebration on 3rd May 2011

• World ORS Week Celebration by Depts. of Paediatrics & Neonatology on 18th July 2011

• World AIDS Day Observation by Depts. of Paediatrics & Neonatology  on 18th July 2011

Short Duration Courses & Lectures

• Lecture session on “Clinical Transformations” on 26th April 2011

• Academic Session on Pathology on 15th June 2011

• AHA Certified BLS & ACLS Course on 22nd to 24th June 2011

• IAP PALS course held on 25th & 26th June 2011

• Academic Session on “Microbiology” on 8th    July 2011

• Excel Paces on 1st, 2nd, 3rd & 4th October 2011

• Basic Laparoscopy Course on 17th & 18th December 2011

• PALS Update on 23rd February 2012

Clinical  Research Projects

DEPARTMENT OF CARDIOLOGY

A randomized double blind controlled trail of the efficacy and safety of POLYCAP versus its components in subject with at least one additional cardio-vascular risk factor.
PI:  Prof. G. Vijayaraghavan

"Evaluation of the anti-anginal efficacy and safety of oral administration of Ivabradine compared to placebo on top of a background therapy with a calcium antagonist (Amlodipine or Nifedipine) in patients with stable angina pectoris. A 6-week randomized double-blind parallel group international multicentric study."
PI:  Prof. G. Vijayaraghavan

 A phase III, randomized, multicenter, double blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism.
PI:  Prof. G. Vijayaraghavan

A phase III, randomized, multicenter, double blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism.
PI:  Prof. G. Vijayaraghavan

A Phase 2, Double blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
PI:  Prof. G. Vijayaraghavan

 
Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients with Permanent Atrial Fibrillation and Additional Risk Factors.

 
Prospective Observation Longitudinal  Registry of patients with stable coronary artery disease.
PI:  Prof. G. Vijayaraghavan

 
A safety and efficacy dose ranging study of GAP-486 in subject with Nonsustained Ventricular Tachycardia and Acute Ischemia.
PI:  Prof. G. Vijayaraghavan  
9.  EPICOR-Asia: Long-term follow up of antithrombotic management pattern In Acute
 Coronary Syndrome patients in Asia
PI:  Prof. G. Vijayaraghavan
 
 
  
 

DEPARTMENT OF INTERNAL MEDICINE

 
Phase 3, Multicentre, Multinational open-label study to evaluate the safety and efficacy of alfimeprase in subjects with occluled central venous access devices

 
A Randomized, double-mind, placebo-controlled multicenter, parallel study assessing the efficacy, safety and dose response of Ramiprill for the Treatment of Hypertension in children and Adolesents

 
A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of Safinamide, as add-on therapy, in patients with idiopathic Parkinson's disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of dopamine agonist and/or an anticholinergic" NW-1015/016/III/2006 & A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the long-term efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic Parkinsons disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of dopamine agonist and/or an anticholinergic NW-1015-018-III/2006

 
A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of Safinamide, as add-on therapy, in patients with idiopathic Parkinson's disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of dopamine agonist and/or an anticholinergic" NW-1015/016/III/2006 & A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the long-term efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic Parkinsons disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of dopamine agonist and/or an anticholinergic NW-1015-018-III/2006

 
Dose Ranging study to evaluate the safety and efficacy of Olmesartan Medoxomil in Children and adolescents with Hypertension

 
A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of the combination of SYR-322 (SYR110322) and Pioglitazone HCI (Actos) in subjects with Type 2 diabetics

 
A phase 2/3, Randomized, Double-blind, Placebo and Active Comparator controlled, Parallel group, multicenter study to determine the safety and efficacy of Metaglidasen (MBX-102) in the treatment of Type 2 diabetics in patients sub optimally controlled on Insulin.

 
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-BT), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE).
PI: Dr. Mathew Thomas

 
A Long Term Open Label Extension study to investigate the long-term safety of SYR-110322 (SYR-322) in subjects with Type 2 Diabetes
PI: Dr. Mathew Thomas

 
A 26-week treatment, multicenter, randomized, doubleblind,double dummy, placebo-controlled, adaptive,seamless, parallel-group study to assess the efficacy,safety and tolerability of two doses of indacaterol (selected from 75, 150, 300 & 600 μg o.d.) in patients with chronic obstructive pulmonary disease using blinded formoterol (12 μg b.i.d) and open label tiotropium (18 μg o.d.) as active controls.
PI: Dr. Mathew Thomas

 
A Phase 3, Multi-Center, Randomized, Double Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-BT), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE).
PI: Dr. Mathew Thomas

 
A Multicenter, Randomised, Double-blind, Placebo-controlled study to determine the efficacy and safety of the combination of SYR-322 (SYR 110322) and Pioglitazone HCl (Actos) in subjects with Type 2 diabetics
PI: Dr. Mathew Thomas

 
A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 plus Pioglitazone HCL (Actos), SYR-322 Alone or Pioglitazone HCL Alone in Subjects with Type 2 Diabetes
PI: Dr. Mathew Thomas

 
A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of the addition of SYR-322 25mg versus Dose Titration from 30 mg to 45 mg of ACTOS® Pioglitazone HCl in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Control on a Combination of Metformin and 30mg of Pioglitazone HCI Therapy
 

 
Dose-Ranging study to evaluate the safety and efficacy of Olmesartan Medoxomil in Children and Adolescents with Hypertension

 
16. A Randomized, Double-Blind Study Comparing the Efficacy And Safety of a fixed combination of fenofibrate and metformin vs metformin alone in patients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statin.
 

 
A 54-week, open-label, Multicenter study to assess the long-term safety and tolerability of the combination of Aliskerin 300mg/Amlodipine 10mg in patients with essential hypertension
PI: Dr. Mathew Thomas
 
 

 
A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks, in drug naive or previously treated (6 weeks washout) type 2 diabetic patients with insufficient glycaemic control

 
A randomized, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite metformin therapy

 
Efficacy of an early administration of L0013CP 10 mg/day versus placebo during 4 weeks in the treatment of infectious diseases induced arthritis painful symptoms. A multicentre, randomised, double blind, placebo controlled clinical trial in adult patients suffering from chikungunya fever

 
An eight week double blind parallel group Multicenter study to evaluate the efficacy and safety of the combination of Aliskiren/HCTZ (300/12.5Mg) and 300/25Mg) in combination with Aliskiren 300Mg in patients with essential hypertension not adequately responsible to Aliskiren 300Mg monotherapy

 
A phase lll, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for evaluation of efficacy and safety of (LMW) Heparin / Edoxaban versus (LMW) Heparin / Warfarin in subjects with symptomatic deep-vein thrombosis and /or pulmonary embolism.
PI. Dr. Gopinatha Menon
23.ProtocolTitle: NAI114373:A Phase lll International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600mg of Intravenous Zanamivir twice daily Compared to 75mg of Oral Oseltamivir twice daily in the Treatment of Hospitalized Adults and Adolescents with Influenza.
PI: Dr. Mathew Thomas

 
 
 A Phase III, Multicentre, Randomized, Double-Blind, Comparative Study to Evaluate the Efficacy
and  Safety of Intravenous Ceftaroline Fosamil Versus Intravenous Ceftriax-one in the Treatment of
Adult Hospitalized Patients With Community-Acquired Bacterial Pneumonia in Asia
PI: Dr. Mathew Thomas

 

DEPARTMENT OF NEPHROLOGY

 
A Multicenter, Randomized, Double-Blind, Study to Evaluate the efficacy and Safety of Sitagliptin versus Glipizide in patients with Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control
PI: Dr. Satish Balan
 

 
A randomized double blind, pacebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist in doubling of serum creatinine, end stage renal or death in patient with type 2 diabetes mellitus and diabetic nephropathy.
PI: Dr. Satish Balan

 
A Randomized, Open-Label, Two-arm, multicentric, Phase III, Comparative study between Novel Erythropoiesis Stimulating Protein (NESP) and Recombinant Human Erythropoietin(r-HuEPO) for treatment of Renal Anaemia in patients with Chronic Renal Failure(CRF) Receiving Hemodialysis. 
PI: Dr. Satish Balan
 

DEPARTMENT OF ENDOCRINOLOGY

 
Effect Gycaemic control of once daily administration of Liraglutide in combination with Metformin versus Glimepiride in combination with metformin in subjects with type 2 diabetesm a 16-week randomized, double blind, double dummy, active control, 4armed, parallel group, multi centre, multi-national trial

 
The durability of Twice daily Insulin Lispro Low mixture compared to Once-daily Insulin Glargine in patients with type 2 diabetes and inadequate Glycemic control

 
Comparison of Insulin Lispro Low mixture with Insulin Glargine when initiating and intensifying insulin therapy as required in patients with Type 2 Diabetes who have inadequate Glycemic control on Oral antihyperglycemic Medication

 
A Multicenter, Double Blind, Randomized, Parallel-Group Study to Demonstrate the Effect of 12 weeks tratment with initial combination of vildagliptin 100mg qd plus Metformin 1000mg bid as Compared to Metformin 1000mg bid in Drug-naïve Patients with Type 2 Diabetes.
PI: Dr. Nishanth Sanalkumar

 
A Multicenter, Double-Blind, randomized, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily as add –on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
PI: Dr. Nishanth Sanalkumar

 

DEPT OF ONCOLOGY

 
“Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients)”
PI: Dr. Jayaprakash Madhavan
    

DEPARTMENT OF GASTROENTEROLOGY  

1. Student Exchange
2. Exchanges of Interns
3. Exchange of Doctors, Specialists and Professors
4. Joint Research Projects
5. PhD in Cardiology 

2. People’s Friends University of Russia, Russia

1. Academic exchanges
2. PFUR scholarship for KIMS Graduates
3. PhD Programs
4. Joint Scientific Research Programs
5. Exchanges of Administrative Staff and Officials

 
Contact Person:

 Mr. Manoj M.T, Sr. Executive-SOCOMER.
Phone: 04703041424 
Mobile: 09744760964
Email: socomer@kimskerala.com